# myasthenia gravis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/myasthenia-gravis

> 7 upcoming FDA catalysts in myasthenia gravis: Cartesian Therapeutics, Inc. (RNAC) on Q1 2027 (topline data readout); IMAAVY (nipocalimab, JNJ) on Jun to Sep 2027 (topline data readout); IMAAVY (nipocalimab, JNJ) on June 2027 (primary completion); IMAAVY (nipocalimab, JNJ) on Sep to Dec 2027 (topline data readout); and 3 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for myasthenia gravis?

7 upcoming FDA catalysts in myasthenia gravis: Cartesian Therapeutics, Inc. (RNAC) on Q1 2027 (topline data readout); IMAAVY (nipocalimab, JNJ) on Jun to Sep 2027 (topline data readout); IMAAVY (nipocalimab, JNJ) on June 2027 (primary completion); IMAAVY (nipocalimab, JNJ) on Sep to Dec 2027 (topline data readout); and 3 more. Press release filed with the SEC (EX-99): "These data strengthen our conviction in Descartes-08 as we approach topline results from our Phase 3 AURORA trial, expected in the first quarter of 2027."" [Calendar and source filings](https://sec-api.dev/indications/myasthenia-gravis)

Source: Press release filed with the SEC (EX-99), accession 0001453687-26-000105, https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/pressrelease9292026.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/indications/myasthenia-gravis#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2026 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | TGTX | myasthenia gravis | completed, positive | "•In June 2026, we announced positive topline data from an ongoing Phase 1 clinical trial evaluating subcutaneous BRIUMVI in patients with AChR-antibody-positive MG and the initiation of a Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000162828026072257/tgtx-20260930.htm)) |
| Q1 2027 | [Cartesian Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/rnac/catalysts) | RNAC | myasthenia gravis | scheduled | "These data strengthen our conviction in Descartes-08 as we approach topline results from our Phase 3 AURORA trial, expected in the first quarter of 2027."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/pressrelease9292026.htm)) |
| Jun to Sep 2027 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT05265273 (A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05265273)) |
| June 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT05265273 (A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05265273)) |
| Sep to Dec 2027 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT07217587 (Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217587)) |
| September 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT07217587 (Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217587)) |
| July 2028 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Myasthenia Gravis | scheduled | "NCT07673744 (A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07673744)) |
| Jul to Oct 2028 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Myasthenia Gravis | scheduled | "NCT07673744 (A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07673744)) |

## Drugs

- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod) (ARGX)
- [IMAAVY (nipocalimab)](https://sec-api.dev/pdufa/nipocalimab) (JNJ)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/myasthenia-gravis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "myasthenia gravis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/myasthenia-gravis

```bibtex
@misc{secapidev_indications_myasthenia_gravis_20261116,
  title        = {myasthenia gravis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/myasthenia-gravis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_myasthenia_gravis_20261116","title":"myasthenia gravis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/myasthenia-gravis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
